Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: James Silverman who wrote (686)	1/8/1998 7:44:00 PM
From: John McCarthy	Respond to of 887

James - Is there any chance we could goto the FDA - at their bequest - and not withstanding the ODAC blowup? Did/is CEPH(SP?) in this posture now. (I realize the indications/ drugs are much different). Regards, John

To: James Silverman who wrote (686)	1/8/1998 8:52:00 PM
From: tnsaf	Read Replies (1) \| Respond to of 887

I must not have made it clear that MTSL's comment of "not particularly negative" was about the affect on Chiron. Regarding approval this year: the FDA does not always follow the advice of an advisory committiee, as in the case of Anesta's Atiq. I'm hoping that if DEPO had an agreement with the FDA about what was required for approval and if they have met those requirements, the ODAC rejection would be overridden. I recall that DepoCyte was going to be approved by the end of the year if an ODAC meeting could not be scheduled. I'm waiting to see. Jason